United Therapeutics (NASDAQ: UTHR) reported Q3 EPS of $4.91, $0.85 better than the analyst estimate of $4.06. Revenue for the quarter came in at $516 million versus the consensus estimate of $493.81 million.

For earnings history and earnings-related data on United Therapeutics (UTHR) click here.